https://news.abbvie.com/2024-05-13-AbbVie-and-Gilgamesh-Pharmaceuticals-Announce-Collaboration-and-Option-to-License-Agreement-to-Develop-Next-Generation-Therapies-for-Psychiatric-Disorders
Gilgamesh will receive an upfront payment of $65 million from AbbVie and is eligible to receive up to $1.95 billion in aggregate option fees and milestones, as well as tiered royalties from mid-single to low-double digits on net sales.
https://news.abbvie.com/2024-05-13-AbbVie-and-Gilgamesh-Pharmaceu...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
